All About Covid: Daniel Ken Diamante, MD

Download as pptx, pdf, or txt
Download as pptx, pdf, or txt
You are on page 1of 40

ALL ABOUT COVID

Daniel Ken Diamante, MD


Coronaviruses
SARS 2003 SARS-COV-2 2019
8,096 infected 199 million infected
774 deaths 4.24 million deaths

2,574 infected
885 deaths

MERS 2012
SARS-CoV-2
Coronavirus 2019
Disease (Covid-19)
Common Symptoms • Fever
• Cough
• Shortness of breath 
Less Common
Symptoms
• Sore throat
• Anosmia
• Dysgeusia
• Anorexia
• Nausea
• Malaise
• Myalgias
• Diarrhea
• Droplet
Transmission • Airborne
• Fomite
Worldwide

• 201 Million infected


• 4.24 Million deaths
• 1.18 billion are fully
vaccinated (15.2%)
United States

• 35.7 million
infected
• 616,000 deaths
• 165.6 million
vaccinated (50.3%)
Philippines
• 1.63 Million
infected
• 28,427 deaths
• 10.3 million
vaccinated (9.5%)
Case-Fatality Rate of 2.2%
A closer look
A closer look
A closer look
COVID-19

• Entry of virus
(ACE II Receptors)
• Two Stages: Early
and Late Phase
• Cytokine storm
• Pulmonary
Edema
Extrapulmonary
Manifestation
Treatment
Oxygen
Support
Remdesivir
Hydroxychloroquine
Hemoperfusion
Nutrition
73% lower odds of having 59% lower odds of having 48% greater odds of having
moderate to severe covid moderate to severe covid moderate to severe covid
Supplements?
Vaccines
Viral Vector

Whole Virus

Protein Subunit Nucleic Acid


 2 doses, 21 days apart
 2 doses, 4-12 weeks apart
 95% efficacy
 70.4% efficacy
 100% effective in preventing severe
 100% effective in preventing severe
disease
disease
 Side effects: Chills, headache, pain,
 Side effects: fatigue, headache,
tiredness, and/or redness and swelling at
feverishness, myalgia
the injection site.
 Rare Adverse Events: thrombosis with
 Rare Adverse Events: anaphylaxis,
thrombocytopenia (8.1 cases in 1 million
carditis (12.6 cases in 1 million)
on 1st dose, 2.3 per million on 2nd dose)
 Approved for 12y.o. and above
1 in 1,117

1 in 188,364

1 in 15,300 1 in 103 1 in 2,535


 1 dose  2 doses, 28 days apart
 72% efficacy  94.1% efficacy
 86% effective in preventing severe  100% effective in preventing severe
disease disease
 Side effects: fatigue, fever headache,  Side effects: chills, headache, pain,
injection site pain, or myalgia tiredness, and/or redness and swelling at
 Rare Adverse Events: Guillain-Barre the injection site
Syndrome   Rare Adverse Events: anaphylaxis,
carditis (12.6 in 1 million)
 2 doses, 21 days apart
 90% efficacy
 2 doses, 28 days apart
 100% effective in preventing severe
 80% efficacy
disease
 Side effects: fatigue, fever headache,
 Side effects: injection site tenderness,
injection site pain, or myalgia
fatigue, headache, muscle pain
 2 doses, 28 days apart
 2 doses, 3 weeks apart
 51% efficacy
 91-96% efficacy
 100% effective in preventing severe
 100% effective in preventing severe
disease
disease
 Side effects: fatigue, fever headache,
 Side effects: fatigue, fever, headache,
injection site pain, convulsions, local
injection site pain, malaise, sore throat
lymphadenopathy, allergic reaction
Official Statement of
Our Church
• The Seventh-day Adventist Church places
strong emphasis on health and well-being.
The Adventist health emphasis is based on
biblical revelation, the inspired writing of
E.G. White (co-founder of the Church), and
on peer-reviewed scientific literature. As
such, we encourage responsible
immunization/vaccination, and have no
religious or faith-based reason not to
encourage our adherents to responsibly
participate in protective and preventive
immunization programs. We value the
health and safety of the population, which
includes the maintenance of “herd
immunity.”
Official Statement of
Our Church
• We are not the conscience of the
individual church member, and
recognize individual choices.
These are exercised by the
individual. The choice not to be
immunized is not and should not
be seen as the dogma nor the
doctrine of the Seventh-day
Adventist Church.

You might also like